NASDAQ:AMDSemiconductors
AMD Shares Rise 4% as Raymond James Forecasts $201 Billion Server-CPU Space
Shares of Advanced Micro Devices rose 4.3% to $476.50 on Tuesday, after a Raymond James upgrade, drawing increased market attention to CPUs as well…
Market intelligence
Latest market intelligence
Fast, evidence-led coverage of the companies and events moving global markets.
All coverage
More market stories
NASDAQ: AMD · Stock move · Server CPU thesis
AMD's 4% rally prices a much larger role for CPUs in agentic AI
AMD snapshot: August 25, 2026, 12:45 EDT · U.S. regular session · Peer snapshots: 12:50–12:59 EDT
AMD price
$476.50
+$19.75 · +4.33%
Market value
$779B
About $32.2B added today.
Volume
11.3M
Shares by 12:40 EDT.
Forward P/E
41.1×
Execution remains expensive.
What changed
$641 target
Raymond James moved AMD to Strong Buy from Outperform and raised its target from $565. The firm models a 44% five-year CAGR for server CPUs, reaching $201B in 2030.
Fresh catalyst: Aug. 25Target upside: 34.5%Analyst: Simon Leopold$641 × 1.63B shares ≈ $1.045T implied value
$1.045T − $779B ≈ $266B valuation gap
$1.045T − $779B ≈ $266B valuation gap
Price and target ladder
Operating proof points
| Measure | Q2 2026 | Y/Y |
|---|---|---|
| Revenue | $11.54B | +50% |
| Data Center | $6.72B | +107% |
| Data Center mix | 58% | Core engine |
| Non-GAAP gross margin | 56% | +13 pts |
| Q3 revenue midpoint | $13.0B | ≈+41% |
2026 consensus
Analysts model $50.8B revenue and $7.57 adjusted EPS. The target case needs earnings to compound faster than sales.
Analyst map
| Source | Rating | Target | Upside at $476.50 | Date |
|---|---|---|---|---|
| Raymond James | Strong Buy | $641 | 34.5% | Aug. 25 |
| Roth MKM | Buy | $650 | 36.4% | Aug. 20 |
| BMO Capital | Buy | $550 | 15.4% | Aug. 20 |
| Bernstein | Buy | $650 | 36.4% | Aug. 13 |
| 54-analyst consensus | Strong Buy | $612.29 | 28.5% | Aug. 25 snapshot |
Peer tape
| Company | Price | Session move | Market cap | Forward P/E |
|---|---|---|---|---|
| AMD | $476.50 | +4.33% | $779B | 41.1× |
| Nvidia | $212.34 | +1.85% | $5.14T | 20.8× |
| Intel | $88.21 | +1.09% | $463.5B | 52.5× |
AMD's outperformance isolates the company-specific upgrade from the broader chip rebound.
Risk monitor
High bar
A slower agentic-AI rollout, weaker server share gains, export controls or price competition would challenge the $201B thesis. Nvidia reports August 26 after the close. Its outlook can reset the entire AI-infrastructure valuation curve.
Sources: AMD market data, S&P Global analyst consensus, AMD Q2 results, AMD EPYC specifications, Raymond James upgrade coverage, Nvidia data and Intel data. Time-sensitive figures are stamped August 25, 2026, 12:40–12:59 EDT.
BiotechnologyNASDAQ:GENB
Generate Biomedicines Shares Up 12% as 103 Million-Share Placement Looms
Shares of Generate Biomedicines Inc. rose 12.3% on Tuesday ahead of its initial significant post-IPO supply challenge. The biotech company was trading at $19.90…
:root{color-scheme:dark;--bg:#071018;--card:#0f1c27;--card2:#122635;--line:#263a48;--text:#edf6fb;--muted:#97adba;--cyan:#4ed7e8;--green:#55d98f;--amber:#ffc86b;--red:#ff7785}*{box-sizing:border-box}body{margin:0;background:linear-gradient(160deg,#071018,#0b1721 48%,#071018);color:var(--text);font:14px/1.45 Inter,ui-sans-serif,system-ui,-apple-system,Segoe UI,sans-serif}.dash{max-width:1140px;margin:auto;padding:22px}.top{display:flex;justify-content:space-between;gap:16px;align-items:flex-start;margin-bottom:14px}.eyebrow{color:var(--cyan);font-weight:800;letter-spacing:.12em;text-transform:uppercase;font-size:11px}h1{font-size:clamp(25px,4vw,42px);line-height:1.05;margin:5px 0}.stamp{color:var(--muted);text-align:right;font-size:12px}.grid{display:grid;grid-template-columns:repeat(12,1fr);gap:12px}.card{background:linear-gradient(145deg,var(--card),#0b1721);border:1px solid var(--line);border-radius:16px;padding:16px;box-shadow:0 10px 28px #0004}.kpi{grid-column:span 3}.wide{grid-column:span 8}.side{grid-column:span 4}.half{grid-column:span 6}.full{grid-column:1/-1}.label{color:var(--muted);font-size:11px;text-transform:uppercase;letter-spacing:.08em}.value{font-size:29px;font-weight:850;margin:5px 0}.up{color:var(--green)}.warn{color:var(--amber)}.sub{color:var(--muted);font-size:12px}.bar{height:9px;border-radius:9px;background:#1a2a35;overflow:hidden;margin:9px 0}.bar i{display:block;height:100%;border-radius:inherit;background:linear-gradient(90deg,var(--cyan),var(--green))}h2{font-size:16px;margin:0 0 12px}.rows{display:grid;gap:9px}.row{display:grid;grid-template-columns:1.25fr .75fr;gap:10px;padding-bottom:8px;border-bottom:1px solid #1e313d}.row:last-child{border:0;padding:0}.row b{text-align:right}.pill{display:inline-block;border:1px solid #315064;border-radius:999px;padding:4px 8px;color:#c8edf4;font-size:11px;margin:2px 3px 2px 0}table{width:100%;border-collapse:collapse;font-size:12px}th,td{padding:8px 7px;border-bottom:1px solid #203542;text-align:right}th:first-child,td:first-child{text-align:left}th{color:var(--muted);font-weight:600}.risk{border-left:3px solid var(--red);padding-left:11px}.good{border-left:3px solid var(--green);padding-left:11px}.timeline{display:grid;grid-template-columns:repeat(4,1fr);gap:8px}.event{background:var(--card2);border-radius:11px;padding:11px}.event b{display:block;color:var(--cyan);margin-bottom:4px}.foot{color:var(--muted);font-size:11px;margin-top:12px}@media(max-width:760px){.kpi,.wide,.side,.half{grid-column:1/-1}.top{display:block}.stamp{text-align:left;margin-top:8px}.timeline{grid-template-columns:1fr 1fr}}@media(max-width:460px){.timeline{grid-template-columns:1fr}.dash{padding:12px}}
NASDAQ · GENB · Live supply test
Generate Biomedicines
The stock is rallying before 103.14 million restricted shares become eligible for resale.
Market snapshot
August 25, 2026 · 12:36 EDT
Regular session open
August 25, 2026 · 12:36 EDT
Regular session open
Share price
$19.90
▲ 12.30% · +$2.18
Intraday range
$17.38–22.67
Record high reached intraday
Volume
3.16M
3.75× three-month average
Quoted market value
$2.55B
≈ $280M added today
Potential supply: the main investor variable
103.14M restricted shares · 80.4% of outstanding25.0M IPO sharesRestricted pool is 4.13× the IPO blockRestrictions expire following the August 25 close. Eligibility does not mean holders will sell; securities-law and affiliate limits still apply.
Price context
IPO price · Feb. 2026$16.00
Premium to IPO+24.4%
52-week low$11.00
52-week high$22.67
Average target$25.60
Target upside+28.6%
Analyst expectations
| Firm | Rating | Target | Upside |
|---|---|---|---|
| Morgan Stanley | Buy | $22 | 10.6% |
| Piper Sandler | Buy | $24 | 20.6% |
| H.C. Wainwright | Buy | $25 | 25.6% |
| Goldman Sachs | Buy | $26 | 30.7% |
| Guggenheim | Buy | $30 | 50.8% |
Six-analyst consensus: Strong Buy. Targets current through Aug. 25, 2026; upside uses $19.90.
Operating signal · Q2 2026
Collaboration revenue$6.3M −37.7% YoY
R&D expense$64.3M +7.7%
Net loss$67.3M +18.5%
H1 operating cash use$138.3M +35.7%
Cash + securities$457.4M
Management runwayInto H1 2028
Catalyst timeline
Feb. 27$400M IPO priced at $16; 25M shares sold.
Aug. 25 closeLock-up expires on 103.14M restricted shares.
Aug. 26Restricted holders may gain resale eligibility, subject to limits.
Sept. 8Phase 1 COPD data for GB-0895 at ERS Congress.
Bull case
Strong volume and a price above the $16 IPO level suggest buyers are absorbing the known supply event. The average analyst target still implies 28.6% upside. Phase 3 severe-asthma studies and near-term COPD data offer clinical catalysts.
Risk case
The eligible resale pool is more than four times the IPO block. Generate has no approved products or product-sales revenue. A disappointing trial result, faster cash use or broad holder selling could compress valuation and bring forward financing risk.
Sources: Generate Biomedicines Form 10-Q filed Aug. 6, 2026; company Q2 release; Reuters IPO report; Yahoo Finance and StockAnalysis market/analyst data. Live figures timestamped Aug. 25, 2026, 12:36 EDT. Calculations use 128.269M shares outstanding and the $19.90 snapshot.
NASDAQ:RRRobotics
Richtech Robotics Stock Jumps 17% as $12 Million Buyback Tests Heavy Dilution
Richtech Robotics Inc. shares jumped 16.7% on Tuesday after the service-robot maker authorized a $12 million stock-repurchase program. The stock traded at $1.89 at…
NASDAQ: RR · Stock move
Buyback signal meets a doubled share count
Richtech Robotics Inc. · Service robotics · Market open
Market data: Aug. 25, 2026
12:21 EDT
12:21 EDT
Share price
$1.89
+16.67%
Previous close: $1.62
Volume
8.05M
1.63× average
20-day average: 4.94M
Market value
$425.4M
About $60.8M added today
Buyback ceiling
$12M
Authorization, not a commitment
Capital structure test
Potential retirement is small beside issuance
Issued base expandedHypothetical full buyback
Buyback math at $1.89
Potential shares6.35M
Shares outstanding225.10M
Market-cap share2.82%
Cash-pool share3.53%
Authorization endAug. 21, 2027
Financial snapshot
Cash + short investments$339.6M
TTM revenue$5.39M
TTM net loss−$4.41M
TTM free cash flow−$29.12M
Price / sales67.7×
Enterprise value / sales4.8×
What changed
$12 million Rule 10b5-1 repurchase plan
The board authorized purchases of Class B stock through Aug. 21, 2027. No minimum purchase is required. The board may modify, pause or end the program without notice.
Investor read-through: Tuesday's $60.8 million market-cap gain is about five times the authorization. The response therefore reflects a valuation signal, not only prospective demand for 6.35 million shares.
Published analyst views
| Firm | Action | Rating | Target | Date | Vs. $1.89 |
|---|---|---|---|---|---|
| Freedom Broker | Upgrade | Hold | $2 | Aug. 16, 2026 | +5.8% |
| H.C. Wainwright | Reiterate | Buy | $6 | Feb. 2, 2026 | +217.5% |
Coverage is sparse. The target spread highlights unusually wide uncertainty around commercialization and valuation.
Watch list
Actual repurchases
Future filings must show whether the authorization was used.Primary
Future filings must show whether the authorization was used.Primary
Share count
New issuance can outweigh buyback activity.225.10M
New issuance can outweigh buyback activity.225.10M
Commercial scale
Nine-month revenue was $3.95M versus a $20.41M net loss.Execution risk
Nine-month revenue was $3.95M versus a $20.41M net loss.Execution risk
Short positioning
Short interest equals 21.2% of shares outstanding.Volatility
Short interest equals 21.2% of shares outstanding.Volatility
NASDAQ:SBUXStock Market
Starbucks Fall Menu Puts 13.6% North America Margin to the Test
Starbucks rolled out its fall menu in the United States on Tuesday, with seasonal beverages set to challenge both customer traffic and profit margins.…
Starbucks • NASDAQ:SBUX • Product catalyst
Fall menu puts traffic gains against a 13.6% margin
Six pumpkin beverages, two longer-lived banana drinks and new food arrive as North America posts stronger transactions and margin expansion.
Trend: starbucks fall menuLaunch: Aug. 25, 2026U.S. market openSBUX
$105.85
▼ 1.53% (−$1.64)
Aug. 25, 2026 • 12:01 EDT • Google Finance
North America revenue
$7.40B
Q3 FY2026 • +7% YoY
Comparable sales
+8.1%
North America • Q3 FY2026
Transactions
+4.5%
North America • Q3 FY2026
Operating margin
13.6%
+30 bps YoY • Q3 FY2026
What the menu is testing
| Group | Count / status | Investor signal |
|---|---|---|
| Pumpkin | 6 drinks; 3 new | Seasonal visits and premium customization |
| Pecan | 3 returning drinks | Familiar recipes and repeat demand |
| Banana bread | 2 new drinks; beyond fall | Longer revenue window |
| Food | 2 new; 1 returning | Beverage-ticket attachment |
North America operating trend
The key test is whether seasonal complexity preserves transaction gains while margin expands.
Share activity
Open $106.85Volume 2.76MAvg. volume 7.17M
Analyst map
12
Buy
8
Hold
0
Sell
| Average target | $119 | +12.4% |
| High / low | $143 / $110 | 20 analysts |
| Baird, Aug. 24 | Buy | $124 |
| TD Cowen, Aug. 18 | Buy | $120 |
Transmission path
Risks: demand may only shift between products; cold-foam customization can slow service; promotions and input costs can offset higher tickets.
Sources: Starbucks Q3 FY2026 release (quarter ended June 28, 2026); Starbucks fall-menu announcements dated Aug. 3 and Aug. 24, 2026; Google Finance quote and analyst data at 12:01 EDT, Aug. 25, 2026. All dollar figures are U.S. dollars.
Market MoversNYSE:BE
Bloom Energy Shares Surge 5% as Pelosi Household Disclosure Sparks $3.3 Billion Market Value Gain
SAN JOSE, California, August 25, 2026, 12:01 EDT - Shares of Bloom Energy climbed 5% after a disclosure from the Pelosi household contributed to…
NYSE: BE · Stock-move dashboard
A 35,000-share-equivalent disclosure moves a $63 billion stock
Bloom snapshot: August 25, 2026, 12:01 EDT · U.S. regular session · Peer snapshots: 11:34 EDT
Share price
$215.10
+5.43% from a $204.02 prior close.
Market value
$63.35B
About $3.26B added during the move.
Volume
8.51M
Shares traded by 12:01 EDT.
Forward P/E
61.8×
Growth expectations leave little room for execution slippage.
Attention amplifier
This compares current underlying share exposure, not the option premiums paid. The stock move is an attention signal; it does not create revenue or contracts.
$11.08 gain × 294.53M shares = $3.26B
$215.10 × 35,000 share equivalents = $7.53M
$3.26B ÷ $7.53M ≈ 433×
$215.10 × 35,000 share equivalents = $7.53M
$3.26B ÷ $7.53M ≈ 433×
Disclosure structure
July 24
10,000 shares plus 100 calls at a $100 strike.
July 28
5,000 shares plus another 100 calls at the same strike.
Aug. 21
Transactions disclosed under the spouse-owner code.
June 17, 2027
Expiry date for all 200 reported call contracts.
Reported ranges total $3M–$12M. Exact option premiums are not disclosed.
Operating engine
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.065B | $401.2M | +165.5% |
| Product revenue | $935.4M | $296.6M | +215.4% |
| GAAP gross margin | 33.4% | 26.7% | +6.7 pts |
| GAAP operating income | $182.2M | -$3.5M | +$185.7M |
| Operating cash flow | $226.4M | -$213.1M | +$439.5M |
2026 revenue guide $3.9–$4.2BNon-GAAP GM ≈34%Non-GAAP EPS $2.55–$2.85
Analyst positioning
Consensus Buy · Average target $275.08 · 27.9% implied upside from $215.10.
Current target spread
| Analyst | Rating | Target | Implied return | Date |
|---|---|---|---|---|
| Bernstein | Hold | $282 | +31.1% | Aug. 18 |
| J.P. Morgan | Buy | $314 | +46.0% | Aug. 3 |
| Wells Fargo | Hold | $176 | -18.2% | July 30 |
| Mizuho | Buy | $242 | +12.5% | July 30 |
The full 29-analyst range runs from $97 to $390. That dispersion reflects both AI-power growth and valuation risk.
Fuel-cell peer tape
| Company | Price | Daily move | Market value | TTM revenue | Net income |
|---|---|---|---|---|---|
| Bloom Energy (NYSE: BE) | $215.10 | +5.43% | $63.35B | $3.11B | $244.9M |
| Plug Power (NASDAQ: PLUG) | $2.275 | +4.84% | $3.18B | $744.1M | -$1.64B |
| FuelCell Energy (NASDAQ: FCEL) | $19.59 | +4.48% | $1.57B | $167.9M | -$225.5M |
Bloom leads on scale and profitability. Similar peer gains suggest the disclosure also lifted attention across fuel-cell equities.
Risk monitor
The disclosed purchases occurred about one month before the market reaction. They do not alter Bloom's contracts, backlog or cash. The stock trades near 62× forward earnings and remains 39% below its 52-week high. AI construction delays, permitting friction, manufacturing defects or margin slippage could compress the multiple.
Sources: Bloom market data, price history, analyst consensus, Bloom Q2 results, congressional transaction records, PLUG data and FCEL data. Time-sensitive figures are stamped August 25, 2026, 11:34–12:01 EDT.
Artificial IntelligenceNASDAQ:SMCI
Supermicro Shares Climb 9% After Cisco Unveils October AI-Factory Sales Program
Super Micro Computer shares climbed 8.63% to $38.21 as of 11:31 EDT. The increase came after news of a distribution deal that integrates its…
NASDAQ: SMCI · Catalyst dashboard
Supermicro’s Cisco channel adds validation before revenue
Market snapshot: August 25, 2026, 11:31 EDT · U.S. regular session
Share price
$38.21
Up 8.63% from a $35.17 prior close.
Equity value
$24.71B
About $1.96B added during the move.
Volume
23.47M
Shares traded by 11:31 EDT on August 25.
Forward P/E
8.81×
Versus 22.68× for Dell and 21.50× for Cisco.
Revenue scale: actuals and fiscal 2027 guidance
The $68.5 billion midpoint implies 75.4% growth. Cisco’s October availability is a channel catalyst; no order value has been disclosed.
Q4 sales +93.2% YoYQ4 gross margin 17.5%New orders >$60B
Analyst positioning
Consensus: Hold · Average target $42.38 · Implied upside 10.9% from $38.21.
Comparable market snapshot
| Company | Price | Daily move | Market value | Forward P/E |
|---|---|---|---|---|
| Super Micro Computer (NASDAQ: SMCI) | $38.21 | +8.63% | $24.71B | 8.81× |
| Dell Technologies (NYSE: DELL) | $453.27 | +4.64% | $292.88B | 22.68× |
| Cisco Systems (NASDAQ: CSCO) | $110.97 | +0.67% | $437.38B | 21.50× |
Prices and valuation metrics: StockAnalysis snapshots at 11:30–11:31 EDT, August 25, 2026. SMCI outperformed the equal-weight daily move of Dell and Cisco by about 6.0 percentage points.
Catalyst path
Aug. 25
Cisco announces Supermicro liquid- and air-cooled compute for its Secure AI Factory with NVIDIA.
October
Cisco plans to begin offering Supermicro rack-scale compute to customers.
Next report
Investors test the $14.5–$15.5 billion fiscal first-quarter sales guide against bookings and delivery capacity.
Investor bridge
Cisco supplies distribution and enterprise validation. Supermicro supplies dense rack-scale compute and liquid cooling. The commercial link is direct, but not yet quantified: an October product path can widen customer access, while revenue depends on orders, pricing, delivery and margin.
| Q4 FY2026 sales | $11.1B | +93.2% YoY |
| Q4 FY2026 gross margin | 17.5% | +8.0 points YoY |
| Q1 FY2027 sales guide | $14.5–$15.5B | Midpoint +34.9% vs. Q4 |
| FY2027 sales guide | $65–$72B | +66.4% to +84.3% |
Risk monitor
Cisco disclosed no committed orders, pricing or margin. Taiwan’s August 24 server-export case adds compliance scrutiny: prosecutors allege 74 of 130 B300 systems reached China through indirect routes, while customs stopped 56. Supermicro says it is not an investigation target and is not accused of wrongdoing.
Sources: Cisco, Supermicro results, Reuters, StockAnalysis market data and analyst consensus. Time-sensitive market figures are stamped August 25, 2026, 11:30–11:31 EDT.
EarningsNYSE:BNS
Scotiabank Shares Surge 5% After Record Profits Lift ROE Past Target
Shares of the Bank of Nova Scotia rose 4.92% on Tuesday following adjusted return on equity hitting 14.2%, surpassing the management’s medium-term target of…
NYSE: BNS · Company / Stock Move
Scotiabank clears its ROE target—and the stock clears consensus
The fiscal Q3 beat was broad: fee income accelerated, every operating segment grew, and revenue expanded faster than costs. The price reaction has already pushed BNS above the average analyst target.
Investor read: the next rerating leg depends on repeatable operating leverage and lower credit costs, not another one-day earnings surprise.
Live U.S. share snapshot
$91.13
+$4.27 · +4.92%
August 25, 2026 · 11:35:12 EDT · NYSE open
Day range $88.46–$91.4052-week high $92.04Adjusted EPS
C$2.28+21.3% YoY · 8.6% above C$2.10 consensusAdjusted ROE
14.2%+1.8 points YoY · 0.2 point above targetRevenue
C$10.54bn+11.1% YoYPositive leverage
+1.88 ptsRevenue growth less expense growthCredit losses
C$1.08bn+3.7% YoY · −11.3% QoQCET1 ratio
13.1%Quarter-end capital bufferTrailing P/E
17.33×At August 25, 11:35 EDTDividend yield
3.72%Forward indicated yieldTuesday price reaction
BNS versus U.S.-listed Canadian bank peers at the same Yahoo Finance market snapshot.
Peer average: +1.00%. BNS outperformance: 3.92 percentage points.
Growth quality: revenue beat costs
Fiscal Q3 2026 versus Q3 2025. Calculated from reported Canadian-dollar figures.
Segment earnings
| Business | Q3 profit | YoY | Signal |
|---|---|---|---|
| Canadian Banking | C$1.07bn | +12% | 19.4% ROE |
| International Banking | C$766m | +8% | Broad growth |
| Global Wealth | C$518m | +23% | C$474bn AUM |
| Global Banking & Markets | C$647m | +37% | Largest gain |
Analyst target map
Consensus: Hold from 14 analysts—2 Strong Buy, 2 Buy, 9 Hold, 1 Sell.
Current price is 1.27% above the average target. The range implies −17.3% to +17.4%.
Capital and valuation
| Market capitalization | $111.29bn |
| One-day value change, approximate | +$5.2bn |
| Quarterly shares repurchased | 8.6m |
| YTD dividends + buybacks | C$6.3bn |
| YTD total return | +24.35% |
| One-year total return | +60.46% |
Market data timestamp: August 25, 2026, 11:35:12 EDT. Market-value change is an estimate based on the quoted percentage move.
What could break the thesis
| Credit | PCL remains 3.7% above last year despite the sequential decline. |
| Valuation | The stock already trades above the average analyst target. |
| Execution | Expenses still rose 9.2%; positive leverage must persist. |
| Currency | Canadian-dollar earnings can translate unevenly for U.S. holders. |
Sources: Scotiabank Q3 releaseReutersYahoo FinanceAnalyst data. All monetary figures are Canadian dollars unless marked with a dollar-only U.S. share price.
NASDAQ:MRNAPharmaceuticals
Moderna Stock Jumps 12% as Wolfe Sees $9.2 Billion Intismeran Opportunity
Moderna shares jumped 12.2% on Tuesday after Wolfe Research abandoned its bearish rating. The move extended a volatile repricing of the vaccine maker's cancer…
NASDAQ: MRNA · STOCK MOVE
Moderna's oncology re-rating
Market snapshot: August 25, 2026, 11:25 EDT · U.S. regular session
+12.18% today
Share price
$155.81
Day range $141.21–$159.20
Trading volume
23.8M
1.80× 3-month daily average
Market value
$62.2B
399.2M shares outstanding
52-week position
88%
$22.28 low · $176.66 high
Session performance: company-specific buying
Prices from Yahoo Finance, captured August 25, 2026, 11:25 EDT.
Analyst targets versus $155.81
UBS
Neutral
$150Barclays
Equal Weight
$125Goldman
Neutral
$120Morgan Stanley
Equal Weight
$89JPMorgan
Underweight
$7723-analyst consensus$95.67 · Hold
S&P Global analyst snapshot, accessed August 25, 2026.
Balance-sheet bridge
Q2 revenue$145M · +2% YoY
Q2 net loss-$782M
Q2 R&D expense$651M · -7% YoY
June 30 cash + investments$6.9B
2026 revenue goalUp to +10%
Year-end cash guide$4.7B–$5.2B
Moderna Q2 2026 results, July 31, 2026.
Catalyst path
Aug. 19INTerpath-001 met its primary and key secondary endpoints. Detailed efficacy data remain pending.
Aug. 24Barclays lifted its target to $125 from $48 and kept Equal Weight.
Aug. 25Wolfe moved to Peer Perform and introduced a $9.2B four-indication peak-sales marker.
Next proofFull Phase 3 data, regulatory discussions, launch timing and personalized-manufacturing economics.
Defense IndustryNASDAQ:DFNS
T3 Defense Shares Soar 22% After Noble Sets $30 Price Target, Evaluates $22 Million Market Value
Shares of T3 Defense Inc. surged 22.34% on Tuesday following Noble Capital’s decision to increase its price target to $30. The market reaction was…
NASDAQ: DFNS · Stock move
T3 Defense: the $30 target meets a 1.66 million-share base
Market data timestamp: August 25, 2026, 11:00 EDT · U.S. regular session open
Price
$13.47
+22.34% vs. Monday
Volume
9.42M
5.7× shares outstanding
Market value
$22.41M
1.66M shares outstanding
Noble target
$30
122.7% above 11:00 price
Three-session price reset
FridayMonday selloffTuesday rebound
Noble Capital scorecard
| Measure | Actual | Noble estimate |
|---|---|---|
| Q2 revenue | $4.0M | $4.5M |
| Gross margin | 25.4% | 11.1% |
| Operating loss | $3.4M | $3.9M |
| Recommendation | Outperform | Target $30, from $20 |
Noble’s research is company-sponsored. The target implies about $49.9M of equity value using the August 14 share count, before potential dilution.
Operating and liquidity signals
| Metric | Verified figure | Read-through |
|---|---|---|
| 1H revenue | $7.65M | Acquisition-led revenue base |
| 1H gross profit | $1.40M | 18.4% gross margin |
| Operating cash use | $9.79M | Exceeds June cash |
| Cash & equivalents | $4.09M | Funding remains material |
| Warrant liabilities | $124.39M | Non-cash volatility and dilution complexity |
Rimon commercial bridge
Preliminary July revenue
$2.60M
2026 YTD revenue
$5.25M
Full-year 2025 revenue
$4.60M
Rimon’s figures are preliminary and unaudited. Its new mobile UAV/counter-UAV line has no disclosed orders yet.
Investor map
| Catalyst / risk | Current evidence | Next proof point |
|---|---|---|
| Analyst rerating | Outperform; target raised to $30 | Orders and estimate revisions |
| Margin execution | Q2 25.4% vs. Noble 11.1% | Repeat margin in Q3 |
| Liquidity | $4.09M cash; $9.79M 1H operating use | Cash conversion or new financing |
| Listing | Equity below Nasdaq’s $10M threshold | Compliance plan due October 5 |
| Micro-float volatility | 9.42M volume on 1.66M shares | Turnover and price stability after catalyst |
Bottom line: Tuesday’s rebound prices in improved operating margins and Noble’s higher target. The durable case still needs booked orders, cash generation and a credible Nasdaq compliance path.
Sources
Stock Analysis real-time market data · Noble Capital research summary · T3 Defense 10-Q · Nasdaq compliance 8-K · Rimon operating update
EarningsNASDAQ:AAOI
Applied Optoelectronics Shares Gain 5% After Company Launches Third $600 Million ATM Program
SUGAR LAND, Texas, August 25, 2026, 11:06 EDT — Applied Optoelectronics stock rose 5% following the announcement of a third at-the-market equity program that…
NASDAQ: AAOI · Stock move
Applied Optoelectronics
Factory expansion is being financed with a third large ATM program.
Market snapshot: August 25, 2026, 11:06 EDT
Regular session open · USD
Regular session open · USD
Share price
$112.85
+4.85% today
Prior close: $107.63
Monday reaction
−13.77%
14.94M shares traded · Aug. 24 close
Market value
$9.58B
84.91M shares outstanding
New ATM capacity
$600M
6.3% of market value at 11:06 EDT
Offering shock and partial rebound
Price path, Aug. 21–25Tuesday volume: 3.51M at 11:06 EDT
The dilution math
*Illustrative full $600M sale at $112.85. The company controls timing and amount; actual issuance can differ.
Read-through: the new authorization equals roughly 6.3% of current equity value, but follows 7.78M shares already sold through June.
Three ATM programs in 2026
| Program | Authorized | Shares sold through June | Net proceeds |
|---|---|---|---|
| First | $500M | 4.83M | $490.0M |
| Second | $600M | 2.95M | $538.8M |
| August | $600M | Not disclosed | Not disclosed |
| Total | $1.70B | 7.78M+ | $1.03B+ |
Where the money is going
Six months ended June 30, 2026. *Cash, cash equivalents and restricted cash.
Growth versus ramp cost
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $191.9M | $103.0M | +86.4% |
| Gross profit | $53.2M | $31.2M | +70.7% |
| GAAP gross margin | 27.7% | 30.3% | −2.6 pts |
| GAAP net loss | −$22.8M | −$9.1M | Loss widened |
| Non-GAAP EPS | $0.06 | −$0.16 | Turned positive |
Q3 operating test
| Guidance | Low | High | Sequential read |
|---|---|---|---|
| Revenue | $255M | $290M | +33% to +51% |
| Non-GAAP gross margin | 29.0% | 30.5% | Above Q2 GAAP margin |
| Non-GAAP net income | $10.1M | $24.0M | Profit ramp |
| Non-GAAP EPS | $0.11 | $0.26 | 92.8M assumed shares |
Analyst recommendations
| Analyst | Firm | Rating | Target | Target vs $112.85 |
|---|---|---|---|---|
| Michael Genovese | Rosenblatt | Buy | $220 | +94.9% |
| Ryan Koontz | Needham | Buy | $190 | +68.4% |
| Simon Leopold | Raymond James | Buy | $178 | +57.7% |
| Tim Savageaux | Northland | Hold | $120 | +6.3% |
| Dave Kang | B. Riley | Hold | $109 | −3.4% |
Six-analyst consensus: Buy. Average target: $163.40, or 44.8% above the 11:06 EDT quote.
What investors must watch
ATM sale pace800G output1.6T rampGross marginCustomer concentration
Upside case
Added capacity converts strong demand into revenue faster than share issuance expands the base.
Downside case
Ramp costs, deployment delays or lower selling prices weaken returns on newly raised capital.
NASDAQ:SWVLStock Market
Swvl Shares Surge 52% as $13 Million PIPE Deal Almost Doubles Outstanding Shares
Shares of Swvl Holdings Corp. surged 52.38% on Tuesday after the mobility firm disclosed a $13 million private placement. The deal provides a significant…
:root{color-scheme:dark;--bg:#08111f;--panel:#101c2d;--panel2:#142338;--line:#263b55;--text:#edf4fb;--muted:#9eb0c4;--green:#45d49b;--cyan:#55c7ff;--amber:#ffbf69;--red:#ff7185;--violet:#a994ff}*{box-sizing:border-box}body{margin:0;background:linear-gradient(145deg,#06101c,#0d1928 55%,#09131f);color:var(--text);font:14px/1.45 Inter,ui-sans-serif,system-ui,-apple-system,BlinkMacSystemFont,"Segoe UI",sans-serif}.wrap{max-width:1180px;margin:auto;padding:24px}.top{display:flex;gap:20px;align-items:flex-end;justify-content:space-between;margin-bottom:18px}.eyebrow{color:var(--cyan);font-size:12px;font-weight:800;letter-spacing:.13em;text-transform:uppercase}h1{font-size:clamp(25px,4vw,42px);line-height:1.05;margin:6px 0 4px}.sub{color:var(--muted);max-width:760px}.stamp{white-space:nowrap;color:var(--muted);font-size:12px;text-align:right}.grid{display:grid;grid-template-columns:repeat(12,1fr);gap:14px}.card{background:linear-gradient(155deg,rgba(20,35,56,.98),rgba(12,25,41,.98));border:1px solid var(--line);border-radius:16px;padding:17px;box-shadow:0 12px 34px rgba(0,0,0,.2)}.metric{grid-column:span 3}.wide{grid-column:span 8}.side{grid-column:span 4}.half{grid-column:span 6}.full{grid-column:1/-1}.label{color:var(--muted);font-size:11px;letter-spacing:.08em;text-transform:uppercase;font-weight:750}.value{font-size:28px;font-weight:850;letter-spacing:-.03em;margin:7px 0 2px}.up{color:var(--green)}.amber{color:var(--amber)}.red{color:var(--red)}.small{font-size:12px;color:var(--muted)}h2{font-size:16px;margin:0 0 12px}table{width:100%;border-collapse:collapse}th,td{text-align:left;padding:9px 7px;border-bottom:1px solid var(--line);vertical-align:top}th{color:var(--muted);font-size:11px;text-transform:uppercase;letter-spacing:.06em}tr:last-child td{border-bottom:0}.tag{display:inline-block;padding:4px 8px;border-radius:999px;font-size:11px;font-weight:800;background:rgba(69,212,155,.12);color:var(--green);border:1px solid rgba(69,212,155,.3)}.tag.risk{background:rgba(255,113,133,.1);color:var(--red);border-color:rgba(255,113,133,.3)}.bar{height:8px;background:#22344b;border-radius:999px;overflow:hidden;margin-top:6px}.fill{height:100%;border-radius:999px;background:linear-gradient(90deg,var(--cyan),var(--green))}.split{display:grid;grid-template-columns:1fr 1fr;gap:13px}.note{padding:12px;border-left:3px solid var(--amber);background:rgba(255,191,105,.06);border-radius:0 10px 10px 0;color:#d9e2ec}.timeline{display:grid;grid-template-columns:110px 1fr;gap:8px 12px}.time{color:var(--cyan);font-weight:800}.event{padding-bottom:10px;border-bottom:1px solid var(--line)}a{color:#78d4ff;text-decoration:none}.sources{font-size:11px;color:var(--muted)}svg{width:100%;height:auto;display:block}.legend{display:flex;flex-wrap:wrap;gap:12px;margin-top:8px;color:var(--muted);font-size:11px}.dot{display:inline-block;width:8px;height:8px;border-radius:50%;margin-right:5px}.kpirow{display:flex;justify-content:space-between;gap:12px;margin:8px 0}.kpirow b{font-variant-numeric:tabular-nums}@media(max-width:850px){.metric{grid-column:span 6}.wide,.side,.half{grid-column:1/-1}.top{align-items:flex-start;flex-direction:column}.stamp{text-align:left}.split{grid-template-columns:1fr}}@media(max-width:500px){.wrap{padding:14px}.metric{grid-column:1/-1}.card{padding:14px}.value{font-size:25px}.timeline{grid-template-columns:1fr}.time{margin-top:4px}}
NASDAQ: SWVL · Financing repricing
Swvl’s cash reset comes with near-100% dilution
A $13 million PIPE nearly triples December cash, while 8.99 million new shares equal 90.23% of the existing share count. The market initially rewarded liquidity over dilution.
Market data: Aug. 25, 2026
10:16 EDT · Regular session
10:16 EDT · Regular session
Share price
$2.24
+52.38% vs. $1.47 close
Trading volume
65.67M
2,463× 26,657 average
Gross PIPE
$13.0M
2.94× Dec. cash
New share block
8.99M
90.23% of existing shares
Price discovery: financing floor versus Tuesday’s market
$0$1$2$3 $1.47$1.446$2.07$2.24$2.33$2.50 Prior closePIPEDay low10:16 EDTOpenDay highThe placement was priced 1.63% below Monday’s close. Tuesday’s 10:16 EDT quote stood 54.91% above the PIPE price, a large gap for a transaction still awaiting closing.
Post-deal ownership math
18.95Mpro forma sharesExisting: 52.57%New: 47.43%
Existing shares9.96M
New shares8.99M
Balance-sheet bridge
Cash at Dec. 31, 2025$4.41M
Gross PIPE proceeds$13.00M
Gross theoretical total$17.41M
Theoretical total excludes transaction fees and all subsequent cash use. Gross proceeds equal 2.94× reported December cash.
Operating signals behind the funding case
| Q1 2026 revenue | $8.2M | +68% YoY |
| GCC revenue | +111% YoY | |
| Recurring revenue mix | 88% | |
| Net dollar retention | 114% | |
| Dollar-pegged revenue | 44% | |
| Operating expenses | 23% of revenue | |
Catalyst timeline
Aug. 25
Swvl announces $13M placement led by Coefficient LP.
Aug. 25
Shares reach $2.24, up 52.38%, on 65.67M volume at 10:16 EDT.
Aug. 27
Expected closing, subject to customary conditions.
After close
Capital earmarked for U.S. expansion, operator lending and balance-sheet support.
Analyst coverage and valuation flags
| Measure | Reading |
|---|---|
| Current recommendations | 1 Sell |
| Buy / Hold | 0 / 0 |
| Consensus target | Not available |
| Quoted market cap | $22.32M |
| Trailing P/E | 18.67× |
| 52-week range | $1.30–$4.01 |
One-rating coverage is too thin for a robust consensus. Quoted valuation uses the pre-closing share count.
What the market is pricing
The rally says immediate liquidity and U.S. expansion capacity outweighed dilution at the opening. Gross proceeds equal 58.24% of the quoted market cap, an unusually large balance-sheet intervention for a company of this size.
What can break the thesis
Closing failure, issuance and resale supply, weak U.S. unit economics, rapid cash deployment or operator-credit losses could reverse the move. Low average volume makes Tuesday’s price discovery especially fragile.
Artificial IntelligenceCloud Computing
Rezolve AI Stock Jumps 22% as Google Cloud Deployment Adds $209 Million in Market Value
Rezolve AI PLC jumped 21.56% to $2.955 by 10:41:55 a.m. EDT on Tuesday. The move lifted its quoted equity value by roughly $209 million.
:root{color-scheme:dark;--bg:#071019;--panel:#0e1a26;--panel2:#122232;--line:#26384a;--text:#eef6ff;--muted:#9eb0c3;--cyan:#4fd1c5;--blue:#6aa9ff;--green:#62d394;--amber:#f6c85f;--red:#ff7b7b}*{box-sizing:border-box}body{margin:0;background:radial-gradient(circle at 12% 0,#13304a 0,transparent 32%),var(--bg);color:var(--text);font:14px/1.45 Inter,ui-sans-serif,system-ui,-apple-system,BlinkMacSystemFont,"Segoe UI",sans-serif}.dash{max-width:1180px;margin:auto;padding:24px}.top{display:grid;grid-template-columns:1.5fr .7fr;gap:18px;align-items:end;margin-bottom:18px}.eyebrow{color:var(--cyan);font-size:12px;font-weight:800;letter-spacing:.14em;text-transform:uppercase}.top h1{font-size:clamp(28px,4vw,50px);line-height:1.02;margin:8px 0}.dek{max-width:760px;color:var(--muted);font-size:16px}.stamp{padding:14px 16px;border:1px solid var(--line);border-radius:14px;background:#0a1520;color:var(--muted)}.grid{display:grid;grid-template-columns:repeat(12,1fr);gap:14px}.card{background:linear-gradient(150deg,var(--panel2),var(--panel));border:1px solid var(--line);border-radius:16px;padding:18px;overflow:hidden}.kpi{grid-column:span 3;min-height:138px}.wide{grid-column:span 8}.narrow{grid-column:span 4}.half{grid-column:span 6}.full{grid-column:1/-1}.label{color:var(--muted);font-size:12px;text-transform:uppercase;letter-spacing:.08em}.value{font-size:30px;font-weight:800;margin:6px 0}.up{color:var(--green)}.sub{color:var(--muted);font-size:12px}.card h2{font-size:18px;margin:0 0 14px}.card h3{font-size:14px;margin:14px 0 6px}.bar{height:10px;background:#07101a;border:1px solid var(--line);border-radius:99px;overflow:hidden}.bar span{display:block;height:100%;border-radius:99px;background:linear-gradient(90deg,var(--cyan),var(--blue))}.metric-row{display:flex;justify-content:space-between;gap:12px;margin:10px 0}.metric-row b{font-variant-numeric:tabular-nums}table{width:100%;border-collapse:collapse;font-size:13px}th,td{text-align:left;padding:10px 8px;border-bottom:1px solid var(--line)}th{color:var(--muted);font-size:11px;text-transform:uppercase;letter-spacing:.06em}.pill{display:inline-flex;padding:5px 9px;border-radius:99px;background:#173348;color:#bfe7ff;font-size:12px;font-weight:700}.pill.risk{background:#3a2427;color:#ffb7b7}.note{padding:12px;border-left:3px solid var(--amber);background:#1c1a12;color:#eadfbf;border-radius:8px}.sources{color:var(--muted);font-size:12px}.sources a{color:#9dd8ff}.spark text{font-family:inherit;fill:var(--muted);font-size:11px}.spark .axis{stroke:#385065;stroke-width:1}.spark .gridline{stroke:#26384a;stroke-dasharray:4 5}.spark .line{fill:none;stroke:var(--cyan);stroke-width:4;stroke-linecap:round;stroke-linejoin:round}.spark .area{fill:url(#fade)}.spark .dot{fill:var(--amber);stroke:#071019;stroke-width:3}.legend{display:flex;gap:14px;flex-wrap:wrap;margin-top:8px;color:var(--muted);font-size:12px}.dotc{width:8px;height:8px;border-radius:50%;display:inline-block;margin-right:5px}.timeline{display:grid;grid-template-columns:repeat(3,1fr);gap:12px}.event{border-top:3px solid var(--blue);padding-top:10px}.event b{display:block}.event small{color:var(--muted)}@media(max-width:820px){.top{grid-template-columns:1fr}.kpi,.wide,.narrow,.half{grid-column:1/-1}.timeline{grid-template-columns:1fr}.dash{padding:15px}.value{font-size:27px}}
NASDAQ:RZLV · Stock move
Technical validation, undisclosed economics
Rezolve AI’s first major distributed-database deployment passed Google’s technical review. The market added about $209 million in equity value before either side disclosed contract revenue.
Market snapshot
August 25, 2026, 10:41:55 EDT
August 25, 2026, 16:41:55 CEST
U.S. market open
August 25, 2026, 10:41:55 EDT
August 25, 2026, 16:41:55 CEST
U.S. market open
Share price
$2.955
▲ 21.56%
Previous close: $2.43
Volume
38.72M
3.01× average
Average: 12.86M shares
Market value
$1.179B
≈ $209M added
Derived from intraday cap and move
Next hard catalyst
Sep. 1
H1 results · 8:30 EDT
Reviewed operating detail expected
One-day repricing
Prior close $2.4310:41:55 EDT · $2.955Catalyst: Google Cloud deploymentInterpretation: investors priced technical validation immediately. Revenue conversion remains unquantified because no contract value, fee schedule or recognized-revenue timing was disclosed.
Deployment scope
Blockchain networks10
Historical data≈100 TB
Checks per block6 cryptographic
Commercial rankFirst major deployment
Disclosure quality
Technical scope: detailed. Contract economics: absent.
Financial scale
| Measure | Period | Reading |
|---|---|---|
| Revenue | FY 2025 | $46.8M audited |
| Gross margin | FY 2025 | 66% audited |
| Net loss | FY 2025 | $(101.4)M |
| Operating cash flow | FY 2025 | $(63.1)M |
| Cash | Dec. 31, 2025 | $111.1M |
| Revenue | H1 2026 | ≈$127M preliminary |
| Revenue guidance | FY 2026 | ≈$360M |
Valuation bridge
≈$970M$1.179BImplied prior10:41:55 EDT +≈$209MThe gain equals roughly 4.5× audited FY 2025 revenue. It does not represent disclosed contract revenue.
Analyst expectations
ConsensusModerate Buy
Ratings6 Buy · 0 Hold · 1 Sell
Average target$11.42
Target range$7–$15
$2.955 current$7 low$11.42 avg.$15 highConsensus collected August 25, 2026; underlying ratings span the prior 12 months.
What matters next
Aug. 25Google deployment announced; shares and volume surge.
Sep. 1 · 8:30 EDTH1 results and investor call; test preliminary $127M revenue.
H2 2026Execution against approximately $360M full-year guidance.
Questions for management
What is the contract value? When does revenue recognition begin? Which costs support the deployment? Can the platform expand beyond 10 networks without lowering margins?
Risk monitor
Economics
No fees, minimum commitment or revenue timing disclosed.
Execution
Preliminary H1 revenue remains unaudited until the September release.
Liquidity
The 2025 Form 20-F reported losses, cash burn and a going-concern warning.
Stock Market
Kura Oncology Shares Surge 9% Following CEO’s $2.35 Million Purchase Over Eight Days
Kura Oncology, Inc. surged 8.87% on Tuesday following a second significant open-market buy from its CEO. The stock was last at $13.50 as of…
NASDAQ: KURA · Company · Stock move
Kura Oncology: a $2.35 million insider-confidence test
Market open snapshot
August 25, 2026 · 10:25 EDT / 16:25 CEST
August 25, 2026 · 10:25 EDT / 16:25 CEST
Share price
$13.50
▲ 8.87% vs. $12.40 prior close
Volume
1.89M
Through 10:25 EDT; recent full-day average ≈2.70M
Market value
$1.20B
88.96M shares outstanding
Intraday range
$12.85–13.73
Open $13.59; new 52-week high
Price path and the two CEO purchases
Daily close / live priceCEO open-market buy
Insider math
Shares bought200,000
Total cost$2.351M
Blended price$11.755
Value at $13.50$2.700M
Paper gain$349K / 14.8%
Disclosed position1,214,650 shares
SEC Forms 4 filed August 17 and August 24, 2026. The latest purchase ranged from $11.47 to $12.85.
The commercial engine
Q2 product revenue$9.1M
New patient starts≈115
Total prescriptions>250
Cash + investments$519.0M
Analyst target map
ConsensusStrong Buy
Analysts15
Average-target upside137%
Targets are opinions, not forecasts of realized value. Consensus data checked August 25, 2026.
Investor bridge
The insider purchase matters because it follows measurable launch traction. KOMZIFTI is growing quickly, but $9.1 million of quarterly product sales remains far below $93.9 million of operating expenses. The stock now asks investors to price faster adoption, a $519 million cash cushion and multiple clinical readouts against continued losses.
Risks
Insider buying can be wrong. Prescription growth may slow. Trial results can fail, and a long development path may require capital despite the stated runway through the first pivotal Phase 3 readout in 2028.
Sources and timing
SEC Forms 4 (Aug. 17 and Aug. 24, 2026); Kura Oncology Q2 release (Aug. 12, 2026); S&P Global/StockAnalysis analyst and tape data. Every market figure is timestamped August 25, 2026, 10:25 EDT / 16:25 CEST.
BlockchainCryptocurrency
BitMine Stock Adds 1% as Ether Treasury Value Nears Market Cap
BitMine Immersion Technologies Inc. rose 1.28% to $24.45 in early Tuesday trade. Volume reached 10.2 million shares by 09:47 EDT. The stock remained among…
NYSE: BMNR · Ethereum Treasury Monitor
BitMine's market value meets its Ether vault
The stock now trades close to company-reported gross holdings. That makes Ether-per-share growth, staking income and dilution the three variables that matter.
Market open · 25 Aug 2026
Share price
$24.45
+1.28% · 09:47 EDT
Market cap
$14.75B
603.23M shares outstanding
Gross holdings
$14.90B
Company report · 23 Aug, 14:00 EDT
Early volume
10.17M
First 17 minutes · 09:47 EDT
Gross holdings rose 31% in one week
Token count grew only 0.6% in the latest week. Ether's company marker price rose 28.9%.
Ether concentration
ETH held
5,847,611
4.8% of reported 120.7M supply
86.7% staked · 5,067,309 ETH
A 1% ETH move changes gross treasury value by about $143M.
Gross holdings per share sensitivity
| ETH scenario | Gross holdings | Per share* |
|---|---|---|
| $2,000 | $12.33B | $20.44 |
| $2,440 reported | $14.90B | $24.70 |
| $3,000 | $18.18B | $30.13 |
*Uses 603.23M shares and holds non-ETH items constant. Gross, not net asset value; excludes liabilities and preferred claims.
Staking income signal
| Seven-day annualised yield | 2.67% |
| Current projected annual revenue | $330M |
| Fully scaled projection | $381M |
| Current projection / market cap | 2.2% |
Management projections, not guidance. Yield, uptime, fees and ETH prices can change.
Analyst lens
Consensus
Strong Buy
3 analysts$31.87 average$25–$40 range
Coverage was last updated July 16. The lowest target is only 2% above the 09:47 EDT price.
Capital structure watch
| Shares outstanding | 603.23M |
| Quarter-over-quarter change | +21.4% |
| Previous close | $24.14 |
| 25 Aug range, 09:47 EDT | $23.59–$24.52 |
Investor test: ETH value per share must outpace new issuance.
What moves BMNR next
ETH spot priceETH acquired per shareStaking yieldValidator uptimeCash issuancePrivate-investment marksCustody and slashing risk
Risk map: crypto trades continuously while BMNR does not. Gross holdings are issuer-reported and include $269M of strategic equity stakes. Market value can diverge sharply from gross asset value.
Sources: BitMine, 24 Aug 2026; BitMine, 17 Aug 2026; StockAnalysis market data, 25 Aug 2026; S&P Global/TipRanks analyst data. Calculations by TechStock²; values rounded.
EnergyNASDAQ:XPON
Expion Energy Shares Fall 16% as $100 Million Funding Plan Outstrips Current Value
Shares of Expion Energy, Inc. dropped 16.5% on Tuesday after investors assessed a financing deal that could greatly expand the battery maker's current equity,…
NASDAQ: XPON · Stock move
Expion Energy
Financing relief meets a much larger dilution envelope.
Market snapshot: Aug. 25, 2026, 09:45 EDT
Regular session open · USD
Regular session open · USD
Share price
$5.18
−16.45% today
Prior close: $6.20
Monday move
+80.49%
Aug. 24 close · 85.98M shares traded
Market value
$4.98M
962,340 shares outstanding
Financing envelope
$100M
$9M closed + $91M investor right
Two-session price shock
Price, Aug. 21–25, 2026Tuesday reading: 09:45 EDT
What moved the stock
Aug. 21 · financing closed$9M of 8% debentures; about $8.2M net.
Aug. 24 · strategic pivot$3.425M cash acquisition of a Louisiana gas prospect.
Aug. 24 · new leadershipKevin Sellers named CEO; company renamed Expion Energy.
By Feb. 15, 2027Target date for a new lateral wellbore, subject to exceptions.
Dilution map
Current common0.96M
Initial conversion2.12M
Initial warrants2.12M
Full scenario25.65M
Illustrative common equivalents at the initial $4.25 price. Additional closings require shareholder approval; later series may differ.
Capital versus commitments
| Item | Amount | Read-through |
|---|---|---|
| Initial net proceeds | $8.20M | 5.3× June cash |
| Acquisition cash paid | $3.425M | 42% of proceeds |
| Maximum leasing commitment | $4.00M | 49% of proceeds |
| Acquisition + leasing | $7.425M | 91% of proceeds |
| First-half operating cash use | $2.607M | Before the pivot |
Operating base
| Metric | Latest | Change/context |
|---|---|---|
| Q2 net sales | $2.03M | −32.1% year over year |
| Q2 gross margin | 32.4% | 20.8% a year earlier |
| H1 operating cash flow | −$2.61M | Cash use increased |
| June 30 cash | $1.54M | Before private placement |
| TTM revenue | $8.21M | As of Aug. 25 market snapshot |
Investor checklist
Shareholder approvalConversion adjustmentsRegistration timingWell economics
Core tension: the first closing improves liquidity, but the financing's potential share supply is far larger than the current float.
Coverage and valuation
No traditional analyst consensus or published price target was available on Aug. 25. P/E measures are not meaningful because earnings are negative.
Terms at a glance
| Security | Term | Investor significance |
|---|---|---|
| Initial debentures | $9M principal; 8% | Automatic preferred conversion after required approval and filing. |
| Series A-1 preferred | $4.25 initial conversion; 8% cumulative dividend from first anniversary | Conversion price can adjust for certain dilutive issues. |
| Initial warrants | 2,117,219 shares; $4.25 exercise; five years | Cashless exercise may apply when resale registration is ineffective. |
| Additional investment right | Up to $91M | Optional for investors; separate preferred series with substantially similar terms. |
BiotechnologyNASDAQ:AMIX
Autonomix Medical Shares Surge 52% After $4.9 Million Warrant Agreement Alters Dilution Outlook
Shares of Autonomix Medical, Inc. surged 52.51% on Tuesday following a $4.9 million warrant exercise that provided the pre-revenue device maker with additional funds.
:root{color-scheme:dark;--bg:#08111c;--panel:#101c2a;--panel2:#142437;--ink:#eef6ff;--muted:#93a7bd;--line:#263a51;--cyan:#39c6dc;--green:#55d68b;--amber:#f6b94a;--red:#ff7780}*{box-sizing:border-box}body{margin:0;background:linear-gradient(145deg,#07101a,#0b1724 52%,#08131e);color:var(--ink);font-family:Inter,ui-sans-serif,system-ui,-apple-system,Segoe UI,sans-serif}.dash{max-width:1120px;margin:auto;padding:22px}.eyebrow{font-size:12px;letter-spacing:.13em;text-transform:uppercase;color:var(--cyan);font-weight:800}.top{display:flex;justify-content:space-between;gap:20px;align-items:end;margin:6px 0 16px}.top h1{font-size:clamp(25px,4vw,42px);line-height:1.03;margin:0}.stamp{color:var(--muted);font-size:12px;text-align:right}.grid{display:grid;grid-template-columns:repeat(12,1fr);gap:12px}.card{background:linear-gradient(180deg,rgba(20,36,55,.96),rgba(13,25,38,.96));border:1px solid var(--line);border-radius:15px;padding:16px;box-shadow:0 14px 34px rgba(0,0,0,.18)}.metric{grid-column:span 3}.wide{grid-column:span 8}.side{grid-column:span 4}.half{grid-column:span 6}.label{font-size:11px;text-transform:uppercase;letter-spacing:.1em;color:var(--muted)}.value{font-size:30px;font-weight:850;margin:6px 0 2px}.sub{font-size:12px;color:var(--muted)}.up{color:var(--green)}.warn{color:var(--amber)}h2{font-size:16px;margin:0 0 12px}p{font-size:13px;line-height:1.5;color:#cad8e7;margin:8px 0}.barrow{display:grid;grid-template-columns:150px 1fr 78px;gap:10px;align-items:center;margin:11px 0;font-size:12px}.track{height:10px;background:#203247;border-radius:20px;overflow:hidden}.fill{height:100%;border-radius:20px;background:linear-gradient(90deg,var(--cyan),#6e9cff)}.fill.green{background:linear-gradient(90deg,#39b879,var(--green))}.fill.amber{background:linear-gradient(90deg,#e58e33,var(--amber))}table{width:100%;border-collapse:collapse;font-size:12px}th,td{text-align:left;padding:9px 7px;border-bottom:1px solid var(--line)}th{color:var(--muted);font-weight:650}td:last-child,th:last-child{text-align:right}.pill{display:inline-block;padding:4px 8px;border-radius:99px;background:#203a4a;color:#81ddeb;font-size:11px}.risk{border-left:3px solid var(--red)}.timeline{display:grid;gap:10px}.event{display:grid;grid-template-columns:94px 12px 1fr;gap:9px;align-items:start}.dot{width:10px;height:10px;border-radius:50%;background:var(--cyan);margin-top:4px;box-shadow:0 0 0 4px rgba(57,198,220,.12)}.event b{font-size:12px}.event span{font-size:12px;color:var(--muted)}svg{width:100%;height:auto;display:block}.foot{margin-top:12px;color:var(--muted);font-size:10px;line-height:1.4}@media(max-width:760px){.metric,.wide,.side,.half{grid-column:span 12}.top{display:block}.stamp{text-align:left;margin-top:8px}.barrow{grid-template-columns:120px 1fr 64px}.dash{padding:14px}}Autonomix Medical
NASDAQ: AMIX · Stock move
Autonomix Medical
financing math
Market open snapshot
August 25, 2026 · 09:50:42 EDT
August 25, 2026 · 09:50:42 EDT
Share price
$8.19
▲ 52.51% vs. $5.37 prior close
Volume
11.0M
2.77× 3-month average
Quoted market cap
$7.95M
Yahoo Finance intraday
Gross cash
$4.9M
Before fees and expenses
The deal is large on both sides of the ledger
The immediate raise equals about 142% of June cash and 61.6% of the quoted market value. Future warrant cash requires exercise and is not assured.
Capital structure
| Instrument | Shares |
|---|---|
| Existing warrants exercised | 857,462 |
| New E-1 warrants | 535,913 |
| New E-2 warrants | 535,913 |
| Replacement coverage | 125% |
New warrants strike at $6.25 and expire five years after issuance.
Share-count sensitivity
0.971M1.829M2.900MAug. 6 reportedAfter exerciseIf new warrants exerciseIllustrative only; excludes other securities and any share changes after August 6.
Balance-sheet pressure
| June quarter | Value |
|---|---|
| Revenue | $0 |
| Net loss | $2.7M |
| Cash used in operations | $3.5M |
| Working capital | $3.1M |
| Funding need to commercialization | $25M–$30M |
The warrant cash helps, but it does not close the disclosed long-term financing gap.
What moved the shares
Aug. 24Company announces exercise of 857,462 warrants at $5.75.
Aug. 25AMIX opens at $7.60 and trades between $7.38 and $8.73 by 09:50 EDT.
Aug. 26Expected closing, subject to customary conditions.
Five yearsNew E-1 and E-2 warrants remain exercisable at $6.25.
Analyst signal
Sparse coverage
$58.80
Two-analyst average target
Maxim Group: Buy, $42 target. Latest cited update: June 2, 2026. Targets predate this financing and carry high uncertainty.
Investor bridge
The immediate cash can fund clinical and device work. The stock's 52.5% gain prices that liquidity quickly. Existing holders must weigh it against an immediate share increase and a larger replacement-warrant overhang.
Risks
Closing conditions, further equity raises, clinical execution, FDA timing, sparse liquidity and a going-concern disclosure all matter. The technology is investigational and has not been cleared for U.S. marketing.
Sources: Autonomix Medical announcement dated August 24, 2026; Yahoo Finance AMIX quote at August 25, 2026, 09:50:42 EDT; Autonomix June-quarter filing; StockAnalysis analyst data last updated June 2, 2026. Calculations are TS2 estimates from disclosed figures and are rounded.